News | February 18, 2008

Cardiologists Implant DES in Three Patients Live from JIM

February 19, 2008 – Clinicians implanted the BioMatrix drug-eluting stent system into the first European patients in a live broadcast during the Joint Interventional Meeting (JIM), held in Rome, Italy, from February 13-15.

The BioMatrix drug-eluting stent system, by Biosensors International Group Ltd., combines a biodegradable PLA and the company’s proprietary limus drug, Biolimus A9.

The two cardiologists who implanted a total of six BioMatrix stents in three cases were Professor Eberhard Grube, M.D., chief of cardiology, the Helios Heart Center in Siegburg, Germany, and Gregg W. Stone, M.D., director of Cardiovascular Research and Education at New York Presbyterian Hospital-Columbia Medical Center, performed the three procedures at the Helios Heart Center in Siegburg.

The first patient to receive a BioMatrix stent was a 71-year-old male suffering from diabetes and hypertension. He was treated with two BioMatrix stents in a procedure performed by Professor Grube that was broadcasted live to the more than 1,500 attendees on the opening day of JIM.

A second patient, a 56-year-old male, received a BioMatrix to treat a previously implanted first-generation DES that had become blocked due to restenosis. Dr. Stone implanted three BioMatrix stents in a third patient, a 57-year-old male suffering from a totally occluded left anterior descending artery (LAD) and a partially occluded right coronary artery (RCA). Despite the complicated patient conditions, doctors were able to implant all six BioMatrix stents with 100 percent procedural success.

“The initial results from these implants are encouraging, and I am very optimistic about the outcome for these patients, based on the consistently positive clinical trial results achieved with BioMatrix,” added Professor Grube, who was responsible for all three live transmissions from Siegburg.

BioMatrix, which received European regulatory approval in January 2008, plans a full European and Asian launch from April 2008.

For more information: www.biomatrix.com

Related Content

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT)...
Superiority of Orsiro Over Xience Demonstrated in STEMI Patients
News | Stents Drug Eluting | September 05, 2019
Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at...
Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...